Soluble form of Fas and Fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia

Chest

Volumn 118, Issue 2, 2000, Pages 451-458

  Kuwano, Kazuyoshi ^a,c   Kawasaki, Masayuki ^a   Maeyama, Takashige ^a   Hagimoto, Naoki ^a   Nakamura, Norio ^b   Shirakawa, Kamon ^b   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Bronchiolitis obliterans organizing pneumonia; Collagen vascular diseases; Fas; Fas ligand; Idiopathic pulmonary fibrosis

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY CELL; LUNG ALVEOLITIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0033870681     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.118.2.451     Document Type: Article

References (23)

1. 1 Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-243
2. 2 Suda T, Takahashi T, Golstein T, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-1178
3. 3 Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154:3806-3813
4. 4 Lowin B, Hahne M, Mattmann C, et al. Cytotoxic-T cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 1994; 370:650-652
5. 5 Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528-530
6. 6 Liebow A. Definition and classification of interstitial pneumonias in human pathology. In: Baset F, George R, eds. Progress in respiration research. Vol. 8. New York, NY: Karger, 1975; 1-33
7. 7 Crystal RG, Bitterman PB, Rennard SI, et al. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med 1984; 310:154-166
8. 8 Crystal RG, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85:769-788
9. 9 Epler GM, Colby TV, McLoud TC, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152-158
10. 10 Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-1762
11. 11 Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nature Med 1996; 2:319-322
12. 12 Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777-1783
13. 13 Tanaka M, Suda T, Takahashi T, et al. Expression of the functional soluble form of Fas ligand in activated lymphocytes. EMBO J 1995; 14:1129-1135
14. 14 Kuwano K, Miyazaki H, Hagimoto N, et al. The involvement of Fas-Fas ligand pathway in fibrosing lung diseases. Am J Respir Cell Mol Biol 1999; 20:53-60
15. 15 American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
16. 16 American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique; 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198
17. 17 Hashimoto S, Kobayashi A, Kooguchi K, et al. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161:237-243
18. 18 Tanaka M, Suda T, Yatomi T, et al. Lethal effect of recombinant human Fas ligand in mice pretreated with propionibacterium acnes. J Immunol 1997; 158:2303-2309
19. 19 Schneider P, Holler N, Bodmer J, et al. Conversion of membrane bound Fas (CD95) ligand to its soluble form is associated with down regulation of its proapoptotic activity and loss of liver injury. J Exp Med 1998; 187:1205-1213
20. 20 Solorzano CC, Ksontini R, Pruitt JH, et al. Involvement of 26-kDa cell-associated TNF alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 1997; 158:414-419
21. 21 Tanaka M, Itai T, Adachi M, et al. Down regulation of Fas ligand by shedding. Nature Med 1998; 4:31-36
22. 22 Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas ligand kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the killing. J Exp Med 1997; 186:2045-2050
23. 23 Kunitake R, Kuwano K, Miyazaki H, et al. The expression of p53, p21 (Waf1/Cip1/Sdi1) and Fas antigen in interstitial pneumonia associated with collagen vascular diseases and granulomatous lung diseases. Eur Respir J 1999; 13:1329-1337